PharmaFocus Today – Page 2 – media

China Resources Pharmaceutical Commercial and Pfizer officially sign a strategic cooperation agreement

On November 26th, China Resources Pharmaceutical Commercial and Pfizer officially signed a strategic cooperation agreement, in which Pfizer will hand over the commercial operation of four heavyweight cancer products in China to China Resources Pharmaceutical Commercial. 01. China Resources wins commercial promotion authorization for four heavyweight cancer drugs On November 26th, China Resources Pharmaceutical Commercial and Pfizer officially signed a strategic cooperation agreement, in which Pfizer will hand over the commercial operation of four heavyweight cancer products in China to China Resources Pharmaceutical Commercial. According to the “Pharmaceutical Representative”, the cooperation will officially begin on December 1st. Employees affected by this cooperation will go to Shanghai for offline communication, and the final employee placement will be completed by the end of next month. The four drugs involved in this transaction have been in the Chinese market for many years, namely AROMASIN, IBRANCE, Pharmarubicin RD, and XALKORI. Among them, Famax was ...
- Source: drugdu
- 56
- November 30, 2024
The first national pharmaceutical public REITs, leading the new development of the pharmaceutical industry

Real estate securitization (REITs) brings about the “three new” trends On November 7th, at the sub forum of the 3rd Green Finance Forum in 2024, Jiuzhou Tong, a leading pharmaceutical circulation enterprise, shared the “three new” trends brought by real estate securitization (REITs). What are the ‘three new’? According to Su Xiling, Deputy General Manager of Jiuzhou Tong Pharmaceutical Group Co., Ltd. and Head of Jiuzhou Production and Investment, firstly, there is a new financing model. REITs, as innovative, non stock, non debt equity financing, provide new financing channels for enterprises, which is conducive to building new production and financing platforms and providing new investment products for the capital market; Secondly, there is a new driving force for development. After the successful issuance of Kyushu Tong’s public REITs, about 80% of the raised funds will be used for infrastructure construction in areas such as pharmaceutical warehousing; The third is the ...
- Source: drugdu
- 42
- November 30, 2024
China Resources Group announces heavyweight cooperation

On November 26th, China Resources Pharmaceutical Commercial and Pfizer officially signed a strategic cooperation agreement, in which Pfizer will hand over the commercial operation of four heavyweight cancer products in China to China Resources Pharmaceutical Commercial. 01 China Resources wins commercial promotion authorization for four heavyweight cancer drugs On November 26th, China Resources Pharmaceutical Commercial and Pfizer officially signed a strategic cooperation agreement, in which Pfizer will hand over the commercial operation of four heavyweight cancer products in China to China Resources Pharmaceutical Commercial. According to the “Pharmaceutical Representative”, the cooperation will officially begin on December 1st. Employees affected by this cooperation will go to Shanghai for offline communication, and the final employee placement will be completed by the end of next month. picture The four drugs involved in this transaction have been in the Chinese market for many years, namely AROMASIN, IBRANCE, Pharmarubicin RD, and XALKORI. Among them, Famax ...
- Source: drugdu
- 41
- November 30, 2024
CSPC Pharmaceuticals’ Ustekinumab is listed

Today (November 26), according to the official website of CDE, Shijiazhuang Pharmaceutical Group’s application for listing of Class 3.3 new drug “Ustekinumab Injection” has been accepted. Ustekinumab is a monoclonal antibody targeting the IL12/23 p40 subunit. It is understood that IL-12 and IL-23 are two naturally occurring cytokines that play a key role in immune-mediated inflammatory diseases. Ustekinumab can inhibit the signal transduction and cytokine cascade mediated by the two cytokines by binding to the p40 subunit shared by the two cytokines and preventing it from binding to the cell surface receptor IL-12β1. The original product of ustekinumab injection was developed by Johnson & Johnson. Since its approval for marketing, its annual sales have continued to grow. In 2023, the global sales of this product successfully exceeded the US$10 billion mark, reaching US$10.858 billion. According to the drug clinical trial registration and information disclosure platform, Shijiazhuang Pharmaceutical Group’s ustekinumab injection ...
- Source: drugdu
- 41
- November 30, 2024
The medical insurance list is released, and the treatment of rejection after transplantation ushers in a new pattern

Today, the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug List (2024) (hereinafter referred to as the “New Medical Insurance List”) was officially announced, and the world’s first and only ROCK2 inhibitor Ilex® (besudinil mesylate tablets) approved for use in patients aged 12 years and above with chronic graft-versus-host disease (cGVHD) who have an inadequate response to glucocorticoid treatment was included in it . The adjusted new version of the medical insurance drug list will be officially implemented on January 1, 2025. 01. Chronic rejection after transplantation: the hidden “killer” and the dilemma of fibrosis cGVHD is the most common and serious complication after allogeneic hematopoietic stem cell transplantation, with an incidence of 30%-70%, and is the main cause of late non-relapse death two years after transplantation. The complexity of cGVHD lies in its invasion of multiple organs – from the skin to the lungs, from the ...
- Source: drugdu
- 38
- November 30, 2024
First domestically produced! Kelun Biotech’s TROP2 ADC “Lukang Satuzumab” approved for marketing

Today, Kelun Biotech announced that its TROP2-targeted ADC drug SKB264 (Lukang Satuzumab) has been approved for marketing for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least 2 systemic treatments (at least 1 of which is for advanced or metastatic stages). Lukang Satuzumab is the first domestically produced and the second global TROP2 ADC drug approved for marketing. This approval is based on the positive results of the Phase III OptiTROP-Breast01 study, which evaluates the efficacy and safety of Lukang Satuzumab compared with chemotherapy as a third-line treatment for patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer (TNBC). The latest results published at ASCO 2024 showed that as of November 30, 2023, compared with chemotherapy, ruconazole reduced the risk of disease progression or death by 69% (HR=0.31, 95% CI: 0.22-0.45, P<0.00001). According to the results of ...
- Source: drugdu
- 36
- November 30, 2024
Big news! Promotion of Pfizer’s four star drugs has changed hands

On the evening of the 26th, Pfizer officially announced a strategic cooperation with China Resources Pharmaceutical Commercial on four varieties. The commercial operation of Pfizer’s four tumor treatment drugs AROMASIN®, IBRANCE®, Pharmorubicin RD®, and XALKORI® in China will be responsible for China Resources Pharmaceutical Commercial. Pfizer stated in an external announcement that Jean-Christophe Pointeau, President of Pfizer China, and Han Yuewei, Deputy General Manager of China Resources Group, attended and witnessed the signing of the contract between the two parties. Exemestane and epirubicin have entered multiple alliance procurement catalogs, and palbociclib and crizotinib are national negotiation varieties, and the prices are far lower than when they were first listed. It is also worth noting that looking at the drugs in the tenth batch of national procurement catalogs released a few days ago, palbociclib has been listed, and another price reduction is inevitable. The cooperation will officially start on December 1. ...
- Source: drugdu
- 35
- November 30, 2024
AnLingKe Biotechnology has completed a $42 million Series A financing to accelerate the global development of bispecific antibodies and ADC products

Allink Biotherapeutics announced today the completion of a $42 million Series A funding round. This round of financing is led by Lanchi Venture Capital, with follow-up investments from Yuansheng Venture Capital, Junlian Capital, and Jianfa Emerging Investment, as well as additional investments from existing shareholders Gao Rong Venture Capital and Mi Fang Health Fund. Gaorong Venture Capital co led the angel round of investment in AnLingKe Biotechnology in 2023. AnLingKe Biotechnology was founded in 2023 and is a biotechnology company focused on innovative drug research and development. Based on its independently developed bispecific antibody and ADC technology platform, the company has laid out a series of innovative product pipelines with the potential for first in class (FIC) and best in class (BIC). The company is committed to developing breakthrough therapies in the fields of oncology and immune diseases, bringing innovative treatment options to patients worldwide. AnLingKe Biology has established an ...
- Source: drugdu
- 57
- November 29, 2024
Kolombotai Biotechnology has obtained the TROP2 ADC drug; Two new drugs from Huadong Pharmaceutical have been approved for market | Early Reference Medicine

On November 27, Kelenbotai Biology announced that the company’s first antibody drug conjugate (ADC) targeting human trophoblast surface antigen 2 (TROP2) for unresectable local advanced or metastatic triple negative breast cancer (TNBC) adult patients who have received at least two kinds of systematic treatment in the past (at least one of which is for advanced or metastatic stage), sac-TMT (formerly SKB264/MK-2870) (Gatalay), was approved by the State Food and Drug Administration to be listed in China. This drug is the first domestically produced and the second globally approved TROP2 ADC drug. Comment: This incident has certain significance for both the company and the domestic innovative pharmaceutical industry. China has become a core participant in global ADC research and development. There are companies in China with strong ADC technology platforms, companies that have accumulated differentiated ADC clinical drugs and strong commercialization capabilities, or companies that have comprehensive and rich technical capabilities ...
- Source: drugdu
- 56
- November 29, 2024
Boston Scientific’s second acquisition this month

On November 25, 2024, Boston Scientific announced that it would acquire infusion pump manufacturer Intera Oncology for an undisclosed amount. Intera Oncology has developed the Intera 3000 hepatic artery infusion pump and chemotherapy drug fluorouridine. Both have obtained FDA approval. This pump can be used for hepatic arterial infusion (HAI) therapy to treat liver tumors mainly caused by metastatic colorectal cancer. The Intera 3000 is the only approved constant current implantable pump for HAI treatment in the United States. 01. Only approved in the United States Intera Oncology is a rapidly growing Boston life sciences company with a mission to change the course of cancer in patients with colorectal and cholangiocarcinoma. Founded by two doctors in 2019, their shared vision is to improve the survival rate of patients with colorectal cancer liver metastases and cholangiocarcinoma by ensuring access to hepatic arterial infusion (HAI) therapy. Hepatic arterial infusion (HAI) therapy is ...
- Source: drugdu
- 46
- November 29, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.